Compare ICMB & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICMB | DARE |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 19.2M |
| IPO Year | 2013 | 2014 |
| Metric | ICMB | DARE |
|---|---|---|
| Price | $0.82 | $1.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 52.3K | ★ 185.6K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | ★ 21.74% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,807,885.00 |
| Revenue This Year | $7.43 | $2,115.12 |
| Revenue Next Year | N/A | $122.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.73 | $1.13 |
| 52 Week High | $3.12 | $3.78 |
| Indicator | ICMB | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 32.77 | 33.48 |
| Support Level | $0.74 | N/A |
| Resistance Level | $1.29 | $1.84 |
| Average True Range (ATR) | 0.05 | 0.14 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 20.00 | 16.16 |
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). The investment objective of the company is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.